Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | PDE1A | P54750 | 2/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.40 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.36 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.35 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.35 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155541 | 0.96 | LMNA (0.40) | LMNAPKMPDE1APDE1BPDE1C | |
| SCHEMBL17458974 | 0.86 | LMNA (0.35) | LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19170534 | 0.86 | LMNA (0.47) | LMNAPKMPDE1APDE1BPDE1C | |
| SCHEMBL16985416 | 0.83 | SMN1; SMN2 (0.38) | PKMMEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL17458949 | 0.83 | PKM (0.45) | LMNAPKMMEN1KMT2AMAPT | |
| SCHEMBL19163453 | 0.80 | MCOLN3 (0.40) | LMNAPKMMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL19222887 | 0.77 | PKM (0.49) | LMNAPKMPDE1APDE1BPDE1C | |
| SCHEMBL17458915 | 0.76 | GPR119 (0.44) | LMNAPKMMAPT | |
| SCHEMBL16975399 | 0.76 | TXNRD1 (0.35) | LMNAMEN1KMT2ARAB9ASMN1; SMN2 | |
| SCHEMBL12283162 | 0.75 | ALDH1A1 (0.44) | LMNAMEN1KMT2AMAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-08-10 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-3172194-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-3172192-A1 | GLUCOSE TRANSPORT INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012481-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
| WO-2016012474-A1 | GLUCOSE TRANSPORT INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226081-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LMNA 2540/4885PKM 344/4885PDE1A 3262/4885 |
| US-20170210738-A1 | GLUCOSE TRANSPORT INHIBITORS | SLC2A1, SLC2A2, SLC2A4 | LMNA 2878/4885PKM 307/4885PDE1A 3566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.